Lijun Zhou1, Zhiqiang Lv2, Jing Shao3, Ying Xu1, Xiaohong Luo1, Yuming Zhang2, Yang Hu2, Wenji Zhang2, Shuhong Luo2,4,5, Jianmin Fang2,4,5, Ying Wang1, Chaohui Duan6, Ruopan Huang7,8,9. 1. Department of Clinical Laboratory, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, People's Republic of China. 2. Raybiotech, Inc, Guangzhou, Guangdong Province, People's Republic of China. 3. Medical Research Center, the Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, People's Republic of China. 4. RayBiotech, Inc, Norcross, Georgia. 5. South China Biochip Research Center, Guangzhou, Guangdong Province, People's Republic of China. 6. Department of Clinical Laboratory, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, People's Republic of China. 1725012289@qq.com. 7. Raybiotech, Inc, Guangzhou, Guangdong Province, People's Republic of China. rhuang@raybiotech.com. 8. RayBiotech, Inc, Norcross, Georgia. rhuang@raybiotech.com. 9. South China Biochip Research Center, Guangzhou, Guangdong Province, People's Republic of China. rhuang@raybiotech.com.
Abstract
BACKGROUND: The human epididymis protein 4 (HE4) may have high specificity in the detection of malignant diseases, making the development of an immunoassay for HE4 essential. METHODS: In our study, a fusion gene was constructed encoded with the HE4 protein. This protein was then produced in the bacterial cells (Escherichia coli) and used to immunize mice in order to eventually generate hybridomas specific to HE4. The hybridoma supernatants were then screened, and four positive anti-HE4 cell lines were selected. These cell lines produce monoclonal antibodies against HE4 epitopes, as demonstrated in the Western blot as well as by direct enzyme-linked immunosorbent assay (ELISA). Using the developed antibodies, we successfully identified several good antibody pairs from the hybridomas, which allowed for the development of a sandwich ELISA to measure HE4 levels. By using the HE4 ELISA, we measured HE4 levels of 60 clinical human serum samples. RESULTS: Compared with the Food and Drug Administration (FDA) approved kit (Roche), our results showed a strong positive correlation to those of the FDA-approved kit. CONCLUSIONS: In summary, highly sensitive antibody pairs were screened against HE4, and a sandwich ELISA was developed as an accurate analytical tool for the detection of HE4 in human serum, which could be especially valuable for diagnosing ovarian carcinomas.
BACKGROUND: The humanepididymis protein 4 (HE4) may have high specificity in the detection of malignant diseases, making the development of an immunoassay for HE4 essential. METHODS: In our study, a fusion gene was constructed encoded with the HE4 protein. This protein was then produced in the bacterial cells (Escherichia coli) and used to immunize mice in order to eventually generate hybridomas specific to HE4. The hybridoma supernatants were then screened, and four positive anti-HE4 cell lines were selected. These cell lines produce monoclonal antibodies against HE4 epitopes, as demonstrated in the Western blot as well as by direct enzyme-linked immunosorbent assay (ELISA). Using the developed antibodies, we successfully identified several good antibody pairs from the hybridomas, which allowed for the development of a sandwich ELISA to measure HE4 levels. By using the HE4 ELISA, we measured HE4 levels of 60 clinical human serum samples. RESULTS: Compared with the Food and Drug Administration (FDA) approved kit (Roche), our results showed a strong positive correlation to those of the FDA-approved kit. CONCLUSIONS: In summary, highly sensitive antibody pairs were screened against HE4, and a sandwich ELISA was developed as an accurate analytical tool for the detection of HE4 in human serum, which could be especially valuable for diagnosing ovarian carcinomas.
Authors: Ingegerd Hellstrom; Patrick J Heagerty; Elizabeth M Swisher; Pu Liu; Jade Jaffar; Kathy Agnew; Karl Erik Hellstrom Journal: Cancer Lett Date: 2010-04-08 Impact factor: 8.679
Authors: Ronny Drapkin; Hans Henning von Horsten; Yafang Lin; Samuel C Mok; Christopher P Crum; William R Welch; Jonathan L Hecht Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Drescher; Pamela Paley; Nicole Urban Journal: Gynecol Oncol Date: 2009-11-28 Impact factor: 5.482
Authors: Chirag A Shah; Kimberly A Lowe; Pamela Paley; Erin Wallace; Garnet L Anderson; Martin W McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay A Bergan; Jason D Thorpe; Nicole Urban; Charles W Drescher Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05 Impact factor: 4.254
Authors: K Huhtinen; P Suvitie; J Hiissa; J Junnila; J Huvila; H Kujari; M Setälä; P Härkki; J Jalkanen; J Fraser; J Mäkinen; A Auranen; M Poutanen; A Perheentupa Journal: Br J Cancer Date: 2009-03-31 Impact factor: 7.640